Enhancing the efficacy of hepatocellular carcinoma immunotherapy by specific inhibition of histone deacetylase 8
Refereed conference paper presented and published in conference proceedings


Full Text

Other information
AbstractHepatocellular carcinoma, as the worldwide fifth leading cancer, has exerted great threats to human health. Immune checkpoint therapies that targeting co-inhibitory molecules like programmed death 1 (PD-1)/PD-ligand 1 (L1) axis exhibited notable anti-tumor effect in various cancer types via enhancing cytotoxicity T lymphocytes (CTL). Unfortunately, responding rate of PD-1/PD-L1-based immunotherapy remains lower than 20% due to lack of CTL infiltration in tumor mass in HCC. We have previously unfolded the oncogenic role of HDAC8 in hepatocellular carcinogenesis, while the detailed immunoregulatory function of HDAC8 has not been studied yet.
Here, we report that HDAC8 inhibition drove remarkable enhancement on tumor CTL infiltration in a chemokine-dependent manner in an orthotopic mouse HCC model. Interestingly, the inhibition of HDAC8 also significantly reduced regulatory T (Treg) cells proportion and ameliorated the suppressive tumor microenvironment. Above all, HDAC8 inhibition hereby substantially improved the efficacy of PD-1/PD-L1 axis blockade to eradicate large hepatoma and extended the surviving period for more than one year with no recurrence observed. Furthermore, we observed that combinatorial treatment further developed potent T cell memory in circulatory system, which protected cured mice from re-challenge of the same HCC cell line. By improving the efficacy of anti-PD-L1 treatment in mouse model, our study further shed lights on how to develop a combinatorial therapy in clinical trial.
All Author(s) ListYu FENG, Weiqin YANG, Jingying ZHOU, Ka Wing Otto CHEUNG, Zhiwei CHEN, Kevin YIP, Ka-Fai TO, Alfred CHENG
Name of ConferenceThe Cold Spring Harbor Asia on Scientific and Technical Advances in Cancer Immunology
Start Date of Conference08/06/2019
End Date of Conference12/06/2019
Place of ConferenceSuzhou
Country/Region of ConferenceChina
Year2019
Month6
Day11
LanguagesEnglish-United Kingdom
Keywordstumor microenvironment, combinatorial therapy, hepatocellular carcinoma, PD-1/PD-L1, HDAC8

Last updated on 2019-02-12 at 15:45